I-CAS 361440-67-7 Ubunyulu > 98.5% (HPLC) Factory
Ruifu Chemical Supply Related Intermediates
I-CAS 361442-04-8
I-CAS 945667-22-1
(R)-1-Boc-3-Aminopiperidine CAS 188111-79-7
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
I-Boc-3-Hydroxy-1-Adamantyl-D-Glycine CAS 361442-00-4
(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo [3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester CAS 361440-67-7
I-2-(3-Hydroxy-1-Adamantyl)-2-Oxoacetic Acid CAS 709031-28-7
Igama leMchiza | (1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo[3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester |
Izithethantonye | I-N-Boc-L-cis-4,5-Methanoprolineamide;N-Boc-cis-4,5-Methano-L-Prolinamide;tert-Butyl (1S,3S,5S)-3-Carbamoyl-2-Azabicyclo[3.1.0]hexane-2-Carboxylate |
Inombolo yeCAS | 361440-67-7 |
Inombolo yeCAT | RF-PI1990 |
Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
Ifomula yeemolekyuli | C11H18N2O3 |
Ubunzima beMolekyuli | 226.27 |
Indawo yokubilisa | 388.9±21.0℃ |
Ukuxinana | 1.228 |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Umgubo oMhlophe |
Ubunyulu / Indlela yokuHlalutya | >98.5% (HPLC) |
Ilahleko ekomisweni | <0.50% |
Intsalela kwi-Ignition | <0.20% |
Ukungcola komntu ngamnye | <1.00% |
Ukungcola ngokupheleleyo | <1.50% |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | I-API ephakathi (CAS: 361442-04-8) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
(1S,3S,5S)-3-(Aminocarbonyl)-2-Azabicyclo[3.1.0]hexane-2-Carboxylic Acid tert-Butyl Ester (CAS: 361440-67-7) iphakathi kwe-API (CAS: 361442 -04-8).(I-CAS: 361442-04-8) i-hypoglycemic yomlomo (i-anti-diabetic drug) ye-dipeptidyl peptidase-4 (DPP-4) inhibitor iklasi yeziyobisi.Uphuhliso lwakwangoko lwaluyiBristol-Myers Squibb kuphela;kwi-2007 i-AstraZeneca idibene ne-Bristol-Myers Squibb ukuze idibanise i-compound yokugqibela kunye nokusebenzisana ekuthengiseni ichiza.NgoJuni 2008, kwabhengezwa ukuba i-Onglyza iya kuba ligama lezorhwebo eliya kuthengiswa phantsi kwayo.I-API (i-CAS: i-361442-04-8) isetyenziswe njenge-monotherapy okanye ngokudibanisa nezinye iziyobisi zonyango lwe-2 yeswekile.Ifunxwa ngokukhawuleza emva kokulawulwa komlomo kwaye ineprofayili ye-pharmacokinetic ehambelana ne-dosing kanye ngosuku.Idlala indima ngokuthintela ukuthotywa kwe-GLP-l.I-GLP-I ziihomoni eziveliswa ngokwemvelo emathunjini emva kokutya.